The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks

Baricitinib is a Janus kinase (JAK) inhibitor that selectively blocks against JAK1 and JAK2 signaling. This study aimed to determine the effect of baricitinib on disease activity based on musculoskeletal ultrasound in patients with rheumatoid arthritis (RA). A total of 20 patients with RA receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seong-Kyu, Jung, Ui Hong, Kim, Ji-Won, Choe, Jung-Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4100
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322478/
https://www.ncbi.nlm.nih.gov/pubmed/34397713
http://dx.doi.org/10.1097/MD.0000000000026739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322478/
https://www.ncbi.nlm.nih.gov/pubmed/34397713
http://dx.doi.org/10.1097/MD.0000000000026739

Ejemplares similares